<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea K Ng, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The non-Hodgkin lymphoma subtype of marginal zone lymphoma represents a group of lymphomas that have been historically classified together because they appear to arise from post-germinal center marginal zone B cells.</p><p>Several marginal zone lymphoma subtypes are recognized in the World Health Organization classification of lymphoid neoplasms:</p><p class="bulletIndent1"><span class="glyph">●</span>Extranodal marginal zone lymphoma (EMZL) of mucosa associated lymphoid tissue (MALT lymphoma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodal marginal zone lymphoma </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Splenic marginal zone lymphoma</p><p></p><p>EMZL arises in a number of epithelial tissues, including the stomach, salivary gland, lung, small bowel, thyroid, ocular adnexa, skin, and elsewhere. While it has a tendency to remain localized to the tissue of origin for long periods of time, it is a clonal B cell neoplasm that frequently recurs locally and has potential for systematic spread and transformation to an aggressive B cell lymphoma.</p><p>This topic review will discuss the treatment of EMZL. The pathogenesis, clinical manifestations, pathologic features, and diagnosis of this disorder is presented separately, as is the diagnosis and management of nodal marginal zone lymphoma, splenic marginal zone lymphoma, and primary cutaneous marginal zone lymphoma.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4739.html" rel="external">"Primary cutaneous marginal zone lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H3915797405"><span class="h1">GASTRIC MZL</span><span class="headingEndMark"> — </span>Gastric marginal zone lymphoma (MZL) is the most common subtype of extranodal marginal zone lymphoma (EMZL). Our approach is generally consistent with that of the European Society of Medical Oncologists and National Comprehensive Cancer Network  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,2</a>]. Areas of significant divergence are noted below.</p><p class="headingAnchor" id="H2039853385"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Patients with newly diagnosed gastric MZL undergo a pretreatment evaluation to determine the extent of disease, <em>Helicobacter pylori</em> infection status, and comorbidities that might impact treatment. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination should include an assessment of the eyes, ears, nose, and throat as well as the lymph node regions, liver, spleen, and skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of nutritional and performance status using the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An esophagogastroduodenoscopy with multiple biopsies taken from each region of the stomach, duodenum, and gastroesophageal junction, and from any site with an abnormal appearance. Endoscopic ultrasound may be used to determine the depth of invasion and involvement of perigastric lymph nodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor biopsy should be tested for <em>H. pylori</em>. If <em>H. pylori</em> is negative by histopathology, evaluate with noninvasive testing (stool antigen test or urea breath test). In addition, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) testing for t(11;18) should be performed to identify MALT1 translocation, which identifies tumors unlikely to respond to <em>H. pylori</em> eradication therapy. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional laboratory studies include a complete blood count with differential, chemistries with liver and renal function, electrolytes, lactate dehydrogenase (LDH), and serum protein electrophoresis. Patients should undergo serologic testing for HIV, hepatitis B virus, and hepatitis C virus. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging to evaluate for distant disease with computed tomography (CT) of the chest, abdomen, pelvis, orbits, and salivary gland, or with whole body combined fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT). Whole body FDG PET/CT is gaining in acceptance, especially for patients with localized disease being evaluated for radiation therapy and in cases of suspected large cell transformation [<a href="#rid1">1-5</a>]. Unlike in some lymphoma subtypes, FDG PET/CT has a low sensitivity for identifying bone marrow involvement in extranodal MZL. In a series of 208 patients with extranodal MZL of whom 16 percent had pathologically confirmed bone marrow involvement, FDG PET/CT had the following test characteristics for identifying bone marrow involvement: sensitivity 39 percent, specificity 99 percent, positive predictive value 87 percent, negative predictive value 90 percent [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate should be performed to confirm suspected early (stage I/II) disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p class="headingAnchor" id="H2392685928"><span class="h2">Staging</span><span class="headingEndMark"> — </span>The Ann Arbor staging system used for most lymphomas is inadequate for the staging of gastrointestinal lymphoma since it does not incorporate information on the depth of tumor invasion known to affect prognosis. Several other staging systems have been proposed, but with limited consensus. The lack of a uniform staging system has hindered the direct comparison of clinical trials. The most widely accepted staging system is the Lugano staging system.</p><p>The Lugano staging system was developed to incorporate measures of distant nodal involvement  (<a class="graphic graphic_table graphicRef65686" href="/z/d/graphic/65686.html" rel="external">table 3</a>) [<a href="#rid7">7</a>]. Stage I or II disease includes a single primary lesion or multiple, noncontiguous lesions confined to the gastrointestinal tract that may have nodal involvement. There is no stage III in the Lugano system. Stage IV disease displays disseminated extranodal involvement or concomitant supra-diaphragmatic nodal involvement.</p><p>For the purposes of this review, we will use the Lugano staging system to describe the treatment.</p><p class="headingAnchor" id="H2443948910"><span class="h2">Stage I or II H. pylori positive</span><span class="headingEndMark"> — </span>The majority of patients with gastric EMZL present with Lugano stage I or II disease with active <em>H. pylori</em> infection. There have been no randomized clinical trials comparing different treatment options in this population. Prospective single-arm trials and retrospective series have evaluated the use of <em>H. pylori</em> eradication, radiation therapy (RT), and surgery. Of these, <em>H. pylori</em> eradication has emerged as the preferred treatment because of its low side effect profile and demonstrated efficacy  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>).</p><p>After initial therapy, patients must be monitored with serial endoscopies to evaluate for disease response, EMZL recurrence, and the development of gastric adenocarcinoma. Treatment failures should be treated with local RT administered with curative intent. Gastric resection is reserved for patients with complications such as perforation, bleeding, or obstruction [<a href="#rid8">8-11</a>].</p><p class="headingAnchor" id="H4154152873"><span class="h3">H. pylori eradication</span><span class="headingEndMark"> — </span>For patients who have stage I or II <em>H. pylori</em>-positive gastric EMZL, we recommend initial <em>H. pylori</em> eradication therapy followed by surveillance rather than immediate RT  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>). There have been no comparisons of various <em>H. pylori</em> eradication regimens in this setting, and a choice among these depends on local resistance patterns and patient-related factors such as penicillin allergy. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p>Several small single-arm trials and larger retrospective series have evaluated <em>H. pylori</em> eradication therapy for the treatment of gastric EMZL. A comparison of these trials is limited by a lack of consensus regarding response evaluation and the definition of complete response (CR). The following is a summary of the results of these trials [<a href="#rid12">12-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Almost all patients were able to successfully eradicate the <em>H. pylori</em> infection, but approximately 20 percent required a second course of <em>H. pylori</em>-directed therapy to do so.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic CR was achieved in 50 to 83 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The median time from <em>H. pylori</em> eradication to CR was 15 months but ranged from five months to over three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After a median follow-up of 6.8 years, one study reported disease relapse in 16 of 74 patients (22 percent) [<a href="#rid19">19</a>].</p><p></p><p>In comparison, patients treated with RT almost always attain a CR and have lower relapse rates (less than 5 percent), but have a potential for more complications [<a href="#rid21">21-25</a>]. Gastrectomy is associated with high morbidity and higher recurrence rates than seen with RT [<a href="#rid8">8-11</a>].</p><p>Up to one-third of gastric EMZL will demonstrate the t(11;18) translocation [<a href="#rid18">18,26-29</a>]; such patients have a lower chance of responding to <em>H. pylori</em> eradication therapy. As an example, one study with a median follow-up of over five years, reported lower rates of continuous CR following antibiotic treatment in tumors with t(11;18) when compared with those without this translocation (30 versus 77 percent, respectively) [<a href="#rid12">12</a>]. Despite this lower response rate, we use <em>H. pylori</em> eradication for the initial management of these patients because of its low toxicity profile and chance of long-term control in a minority of patients.</p><p>Few studies have evaluated the use of adjuvant chemotherapy in patients achieving a CR. A randomized trial of adjuvant <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> versus observation in patients achieving histologic CR with <em>H. pylori</em> eradication failed to show a progression-free or overall survival benefit [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3009630814"><span class="h3">Response evaluation</span><span class="headingEndMark"> — </span>Patients initially treated with <em>H. pylori</em> eradication therapy are evaluated after the completion of treatment to determine whether the <em>H. pylori</em> was successfully eradicated and whether there has been a tumor response  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm eradication – At least four weeks after the completion of <em>H. pylori</em> eradication therapy, testing should be performed to confirm eradication of infection. Up to 20 percent of patients will require a second <em>H. pylori</em> eradication regimen to fully eliminate the infection. We offer up to three eradication regimens before pursuing alternative therapies. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Confirm eradication in all patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess tumor response – After successful eradication of <em>H. pylori</em>, patients should undergo periodic upper endoscopy with multiple biopsies to evaluate for tumor response and monitor for relapse [<a href="#rid31">31,32</a>]. While this has not been formally studied, we typically perform endoscopy with biopsies every three months until a histologic CR is attained, and then perform endoscopy every six months for at least the first two years and then suggest endoscopy every 18 months and as clinically indicated. Surveillance can stop in asymptomatic patients once two sequential endoscopies show no abnormalities on biopsy. Surveillance endoscopy in patients with persistent chronic gastritis, gastric atrophy, and gastric/intestinal metaplasia is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16636.html" rel="external">"Gastric intestinal metaplasia", section on 'Endoscopic surveillance in selected patients'</a>.)</p><p></p><p>Unfortunately, there has been little consensus regarding what constitutes a CR of gastric EMZL. The Wotherspoon histological index  (<a class="graphic graphic_table graphicRef78881" href="/z/d/graphic/78881.html" rel="external">table 4</a>) originally devised to differentiate between gastritis and EMZL at the time of diagnosis has been reported to have a high rate of inter-observer variation when applied to post-treatment biopsy specimens [<a href="#rid12">12,33,34</a>]. Using these criteria, patients who demonstrate grade 0 to 2 lesions are considered to have a histologic CR, while grade 3 lesions are classified as a partial response (PR). In contrast, the GELA score defines a histological CR as a normal or empty lamina propria and/or fibrosis with absent or sparse plasmacytes and lymphoid cells in the lamina propria without lymphoepithelial lesions [<a href="#rid33">33,35</a>]. While there appears to be a low degree of inter-observer variation when the GELA score is used, prospective studies are needed to validate its prognostic value [<a href="#rid33">33</a>].</p><p>While successful treatment with radiation usually results in the disappearance of B cell clonality [<a href="#rid36">36</a>], treatment with <em>H. pylori</em> eradication therapy often demonstrates persistent B cell clonality on molecular studies [<a href="#rid37">37</a>]. The ultimate clinical significance of persistent clonality in these treatment settings is unclear [<a href="#rid17">17,37-39</a>]. As an example, in a study of patients achieving histologic CR following eradication of <em>H. pylori</em>, there was no significant difference in the rate of histologic relapse between those who did or did not achieve molecular remission [<a href="#rid17">17</a>]. We reserve molecular testing for patients on clinical trials and define CR in clinical practice based upon histologic criteria.</p><p class="headingAnchor" id="H4178052329"><span class="h3">Treatment failures</span><span class="headingEndMark"> — </span>Approximately 20 to 30 percent of patients do not respond to <em>H. pylori</em> eradication therapy or demonstrate relapse during follow-up. Histology should be reviewed carefully at this time to confirm the presence of EMZL and absence of a more aggressive lymphoma, such as diffuse large B cell lymphoma [<a href="#rid40">40</a>].</p><p>The appropriate timing of second-line therapy is complicated by the sometimes slow response to <em>H. pylori</em> eradication therapy with attainment of CR taking up to three years. In general, we consider RT such as that given for <em>H. pylori</em>-negative gastric EMZL if disease is still present after 12 to 18 months  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>). (See <a class="local">'Stage I or II H. pylori negative'</a> below.)</p><p>Patients with relapsed EMZL have five-year survival rates as high as 80 to 90 percent. Treatment options include localized radiation for disease limited to the stomach or perigastric nodes and single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or chemoimmunotherapy for those with Lugano stage IV disease. (See <a class="local">'Advanced stage'</a> below.)</p><p class="headingAnchor" id="H756493213"><span class="h2">Stage I or II H. pylori negative</span></p><p class="headingAnchor" id="H1864172884"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>A minority of patients with Lugano stage I or II gastric EMZL will not demonstrate active infection with <em>H. pylori</em> at the time of diagnosis. For such patients, we suggest local RT administered with curative intent rather than <em>H. pylori</em> eradication therapy or other therapies  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>). This is principally due to the high CR rates, low toxicity profile, and long-term remissions associated with this approach. Support for this approach is even stronger in tumors that demonstrate the t(11;18) translocation, as these tumors have a lower chance of responding to <em>H. pylori</em> eradication therapy [<a href="#rid12">12</a>]. If t(11;18) is negative and <em>H. pylori</em> is negative on biopsy, we sometimes offer <em>H. pylori</em> eradication therapy in addition to RT depending on the quality of the biopsy specimen. Immunotherapy and chemotherapy are reserved for patients failing or recurring after RT and those with Lugano stage IV disease.</p><p>Our approach for this population is consistent with that of the National Comprehensive Cancer Network, but differs slightly from that of the European Society of Medical Oncologists (ESMO) [<a href="#rid1">1,2</a>]. ESMO considers a trial of <em>H. pylori</em> eradication therapy reasonable since testing for <em>H. pylori</em> is not 100 percent sensitive and responses to eradication therapy have been reported.</p><p>The data regarding these and other treatment options come from retrospective studies and small, single agent prospective trials. There have been no clinical trials directly comparing these treatment strategies.</p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy – Local RT (total dose of 25 to 30 gray [Gy] administered over three to four weeks) results in high rates of overall and complete responses (100 and 98 percent, respectively) for stage I or II gastric EMZL with few local relapses and five-year disease-free and overall survival rates ranging from 94 to 98 and 77 to 94 percent, respectively [<a href="#rid21">21-25,41-45</a>]. In one study, estimated median progression-free and overall survival were over 17 years [<a href="#rid44">44</a>]. A small series suggests that 24 Gy may be adequate [<a href="#rid41">41</a>]. Toxicities are limited in duration and include anorexia, malaise, nausea, and/or dyspepsia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single-agent rituximab – Single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> results in overall and complete response rates of approximately 77 and 46 percent, respectively [<a href="#rid46">46-49</a>]. Rituximab therapy is relatively well tolerated but carries risks of infusion reactions and of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incorporation of chemotherapy – When <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is combined with chemotherapy, the response rates increase, as do the associated toxicities. Unlike RT, chemoimmunotherapy is not curative. Data regarding the efficacy of chemoimmunotherapy and choice of regimen in marginal zone lymphoma are described separately. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Incorporation of chemotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There have been case reports of tumor responses to <em>H. pylori</em> eradication in <em>H. pylori</em>-negative patients, presumably due to false negative results of <em>H. pylori</em> testing [<a href="#rid15">15,19,50,51</a>]. We do not offer <em>H. pylori</em> eradication to patients without evidence of active <em>H. pylori</em> infection.</p><p></p><p class="headingAnchor" id="H1416818644"><span class="h3">Restaging</span><span class="headingEndMark"> — </span>We perform serial endoscopies at one and two years after completion of RT. If the patient is disease-free after two years, we do not perform further endoscopies unless new symptoms develop. As described above, there is no general consensus regarding the preferred response criteria. (See <a class="local">'Response evaluation'</a> above.)</p><p class="headingAnchor" id="H2857139717"><span class="h3">Persistent disease</span><span class="headingEndMark"> — </span>Most patients with Lugano stage I or II <em>H. pylori</em>-negative gastric EMZL can achieve a CR with initial RT. Those patients who fail to achieve a CR may be candidates for treatment with single agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or a combination of rituximab and chemotherapy as described in the section above. (See <a class="local">'Initial therapy'</a> above.)</p><p>Patients who choose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or combination therapy for their initial management may be candidates for RT if there is persistent disease or if they develop localized relapse. Those who progress despite single-agent rituximab, combination therapy, and RT are treated with serial chemotherapy regimens. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Choice of therapy'</a>.)</p><p class="headingAnchor" id="H3815891314"><span class="h2">Advanced stage</span><span class="headingEndMark"> — </span>Patients with Lugano stage IV gastric EMZL are treated with <em>H. pylori</em> eradication therapy if they have active <em>H. pylori</em> infection, and then generally observed until the development of symptoms at which time they undergo treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and/or chemotherapy. For those without active <em>H. pylori</em> infection, treatment is postponed until symptoms develop. The preferred therapy at progression is not clearly defined and most data in this population come from retrospective series or extrapolation of data from other indolent non-Hodgkin lymphomas.</p><p>Our approach to such patients is similar to that used for nodal marginal zone lymphoma. This is described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Choice of therapy'</a>.) </p><p class="headingAnchor" id="H2186239355"><span class="h1">NON-GASTRIC MZL</span></p><p class="headingAnchor" id="H3091029894"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Extranodal marginal zone lymphoma (EMZL) can involve the ocular adnexa, lung, lacrimal and salivary glands, thyroid, small intestine, breast, synovium, dura, skin, and soft tissues. The treatment of non-gastric EMZL depends principally on the stage of disease and area involved  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 5</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with involvement of a single extralymphatic site (IE) or a lymph node extending into a contiguous extralymphatic organ or tissue (IIE) are generally treated with local therapy or managed expectantly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In comparison, more advanced disease is treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and/or chemotherapy in a similar fashion to nodal marginal zone lymphoma. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Treatment'</a>.)</p><p></p><p>The pretreatment evaluation usually involves extensive staging studies, which differ depending on the site of disease.</p><p>Of importance, patients with EMZL of any stage who demonstrate coexistent large cell lymphoma are treated as diffuse large B cell lymphoma. (See <a class="local">'Histologic transformation'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h3">Stage I or II disease</span><span class="headingEndMark"> — </span>Involved-site radiation therapy (ISRT) is the preferred treatment for most patients with involvement of a single extralymphatic site (IE) or a lymph node extending into a contiguous extralymphatic organ or tissue (IIE). Alternatives for patients who are not ideal candidates for RT due to tumor location (eg, lung) or comorbidities include initial observation, single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or resection. </p><p>Select patients may be candidates for antimicrobial therapy directed at an underlying infection. Adjuvant chemotherapy has not improved disease-free survival (DFS) or overall survival (OS) in non-gastric EMZL. Specific considerations based on the site of involvement are discussed separately. (See <a class="local">'Site-specific considerations'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiotherapy</strong> – ISRT to 24 gray (Gy) in 12 fractions is the principal therapy for most cases of stage I EMZL [<a href="#rid42">42,52</a>]. This lymphoma is very sensitive to radiation and doses should not exceed 30 Gy. With standard RT doses, rates of complete response (CR) and local control are in excess of 90 percent [<a href="#rid23">23,44,53-66</a>]. In contrast, low-dose radiation (eg, 4 Gy in two fractions) is generally not appropriate for treatment with curative intent since it is associated with a higher local relapse rate [<a href="#rid67">67,68</a>]. However, a low-dose response-adapted approach can be considered in selected patients with small volume disease, especially in those with significant comorbidities or toxicity concerns due to location of involvement [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent </strong><strong>rituximab</strong> – In one study of single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in 35 patients with EMZL, approximately half with stage I or II disease, the overall and complete response rates were 73 and 43 percent, respectively [<a href="#rid48">48</a>]. The median duration of response was 10.5 months overall but was longer among those who were chemotherapy-naïve. Rituximab therapy is relatively well tolerated but carries risks of infusion reactions and of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Surgery may be used as initial therapy for stage I or II EMZL in locations not amenable to RT, although this is uncommon given the low doses of radiation required [<a href="#rid21">21,23,55,63,70-74</a>]. In addition, the pathologic diagnosis of EMZL may become apparent only after a resection has taken place. If EMZL is diagnosed with an excisional biopsy and there is no evidence of residual disease, patients may be followed with close observation. However, if an initial surgical specimen demonstrates positive margins, adjuvant involved-field RT is administered to avoid local recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjuvant chemotherapy</strong> – While EMZL has a high response rate to chemotherapy, the benefit of adjuvant chemotherapy after RT has yet to be proven [<a href="#rid75">75,76</a>].The addition of anthracycline-based chemotherapy to RT in one randomized study of 98 previously untreated patients with stage IE primary orbital EMZL did not improve the results obtained following RT alone [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobials</strong> – Patients with hepatitis C virus (HCV) infection not requiring immediate lymphoma-directed therapy should be evaluated for antiviral treatment. A number of reports, primarily from Europe, have described remissions following HCV treatment in patients with indolent lymphoma, including marginal zone lymphoma. In a multicenter, phase 2 trial of genotype-appropriate direct-acting antiviral therapy in patients with HCV infection and indolent lymphoma not requiring immediate lymphoma-directed therapy, all patients achieved a sustained virologic response, 45 percent achieved a tumor response, and the three-year progression-free survival was 76 percent [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">"Initial treatment of stage II to IV follicular lymphoma", section on 'Patients with hepatitis C'</a>.)</p><p></p><p class="bulletIndent1">For patients with MZL of the ocular adnexa, there is mixed evidence regarding the use of antibiotics directed against the presumed causative agent, <em>Chlamydia psittaci</em>. (See <a class="local">'Ocular adnexa MZL'</a> below.)</p><p></p><p class="bulletIndent1">Unlike in gastric EMZL, the benefit of <em>H pylori</em>-directed antibiotic therapy for non-gastric EMZL is unproven. In a prospective study of 77 patients with non-gastric EMZL, evidence for infection with <em>H. pylori</em> was present in 45 percent [<a href="#rid79">79</a>]. However, in the 16 <em>H. pylori</em>-positive patients receiving antibiotic treatment before anti-lymphoma therapy, partial regression of the lymphoma was seen in only one patient (ie, regression of a colonic lesion in a patient with both parotid and colonic disease).</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Stage III or IV disease</span><span class="headingEndMark"> — </span>The treatment of patients with non-gastric extranodal disease plus multiple sites of nodal involvement (stage III or IV) is not clearly defined, and most data in this population come from retrospective series or extrapolation of data from other indolent non-Hodgkin lymphomas. Our approach to such patients is similar to that used for nodal marginal zone lymphoma. This is described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Choice of therapy'</a>.) </p><p class="headingAnchor" id="H8"><span class="h3">Follow up</span><span class="headingEndMark"> — </span>Long-term treatment success with any therapy for EMZL is limited. As an example, a study of patients with EMZL who had achieved CR after initial therapy described relapses in 32 of 86 at a median time of 47 months (range: 14 to 307 months), suggesting the need for long-term observation of these patients [<a href="#rid80">80</a>]. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p>Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse or progression. The frequency and extent of these visits depend on the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. We generally follow patients every three to six months for the first two years and then every 6 to 12 months out to five years.</p><p class="headingAnchor" id="H1924292674"><span class="h2">Site-specific considerations</span></p><p class="headingAnchor" id="H3203737297"><span class="h3">Ocular adnexa MZL</span><span class="headingEndMark"> — </span>Most patients with EMZL of the ocular adnexa present with stage I or II disease; we perform extensive staging studies to identify the up to one-quarter of patients with multifocal involvement, including bilateral disease [<a href="#rid81">81,82</a>], although other experts suggest a less aggressive staging approach given the relatively low yield of some studies (eg, bone marrow biopsy, incorporation of PET) [<a href="#rid83">83</a>]. A tumor, node, metastasis (TNM) staging system has been proposed for ocular adnexa lymphomas but is not commonly used in clinical practice [<a href="#rid84">84</a>]. We perform the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination includes a detailed assessment of the eyes, ears, nose, and throat as well as the lymph node regions, liver, spleen, and skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies include complete blood count with differential, chemistries with liver and renal function, electrolytes, and lactate dehydrogenase (LDH). Patients should undergo serologic testing for HIV, hepatitis B virus, and hepatitis C virus. We do not routinely test for chlamydial infection on diagnostic tissue because studies in the United States patient population suggest infection is very rare, unlike the epidemiology in Italy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging examination includes gadolinium-enhanced magnetic resonance imaging (MRI) of the orbits and near structures plus either CT of chest, abdomen, and pelvis, or whole-body positron emission tomography/computed tomography (PET/CT).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate is performed by some contributors to confirm suspected stage I or II disease in all patients, while others limit this to select patients (eg, those with multifocal disease).</p><p></p><p>The data regarding treatment of these patients come from retrospective series and small prospective studies. We offer localized RT to most patients but recognize that selected patients may reasonably choose observation after initial resection. Other experts may offer antibiotics or intralesional <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, although the data regarding these approaches are less clear.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized RT</strong> – For most patients with stage I or II EMZL of the ocular adnexa that can be encompassed in a single radiation field, we suggest localized RT rather than other therapies. Radiation is typically administered at a dose of 24 to 25 Gy in conventional daily fractions [<a href="#rid42">42,52</a>]. The clinical target volume (CTV) generally includes the whole orbit, but for conjunctival cases, the CTV can include the conjunctival reflection to the fornices without including the entire orbit. With this approach, in-field relapses are uncommon and approximately 35 to 40 percent will relapse within five years, often at a contralateral or distant site [<a href="#rid23">23,85-88</a>]. At these doses, early radiation toxicity includes cutaneous and/or conjunctival reactions, while long-term effects include cataract formation (30 to 50 percent), xerophthalmia (20 to 40 percent), and retinopathy (2 percent). While lens shielding may reduce the risk of cataract development, it may also increase the risk of local relapse. Higher doses (eg, 36 Gy) should not be used and can result in ischemic retinopathy, optic atrophy, corneal ulceration, and vision loss due to neovascular glaucoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation</strong> – Select patients may be observed following initial resection. The pathologic diagnosis of EMZL may become apparent only after a resection has taken place. Complete resection may be possible for patients with conjunctival and lacrimal gland lesions. Patients with negative surgical margins may be observed initially. Adjuvant involved-site RT is offered to those with positive surgical margins for local control. Older adults and asymptomatic patients may also select initial observation following surgery. In a retrospective study with a median follow-up of seven years, 25 of 36 patients (69 percent) with marginal zone lymphoma of the ocular adnexa did not require therapy beyond biopsy or resection [<a href="#rid89">89</a>]. The median time to the initiation of therapy was 4.8 years and only two patients died due to progressive lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – There is controversy regarding the use of antibiotics directed against the presumed causative agent, <em>Chlamydia psittaci</em>. Antibiotics have shown variable efficacy against EMZL [<a href="#rid90">90-95</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an international phase 2 trial of 44 patients with stage I ocular adnexal EMZL, 34 (77 percent) had detectable <em>C. psittaci</em> and were treated with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid94">94</a>]. An at least partial response was seen in 22 patients (six complete). At a median follow-up of 37 months, the estimated rate of PFS at five years was 55 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a Korean trial, 90 patients with EMZL of the ocular adnexa were treated with one or two three-week cycles of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid96">96</a>]. An at least partial response was seen in 24 patients (27 percent), four of which were complete. After a median follow-up of 40 months, the estimated five-year PFS was 61 percent. Approximately one-third had local recurrence responsive to chemotherapy and/or RT.</p><p></p><p class="bulletIndent1">The long-term prognosis following antibiotic therapy is not known, however, and patients considered for antibiotic therapy alone are best treated on specific protocols and require long and careful follow-up care by an experienced hematologist/oncologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intralesional </strong><strong>rituximab</strong> – In a phase 2 study, 20 patients with EMZL of the ocular adnexa refractory to prior therapy were treated with serial intralesional injections of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid97">97</a>]. For those with no response after four injections, rituximab injections were supplemented with autologous serum. The overall response rate was 65 percent (12 complete, 1 partial). After a median follow-up of 42 months, 12 patients remained free of relapse. The treatment was well tolerated; there were three mild local reactions. </p><p></p><p>Response assessment and long-term follow-up includes care from an ophthalmologist and imaging with MRI. The frequency of imaging depends on the comfort of the patient and clinician. (See <a class="local">'Follow up'</a> above.)</p><p class="headingAnchor" id="H3403849435"><span class="h3">Salivary gland MZL</span><span class="headingEndMark"> — </span>Staging of patients with EMZL of the salivary glands includes both an assessment of disease extent as well as studies for associated conditions. We perform the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination includes a detailed assessment of the eyes, ears, nose, and throat as well as the lymph node regions, liver, spleen, and skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies include complete blood count with differential, chemistries with liver and renal function, electrolytes, LDH, and serologic testing for HIV, hepatitis B virus, and hepatitis C virus. Patients should be evaluated for Sjögren's disease. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Diagnosis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging examination includes gadolinium-enhanced MRI of the orbits and near structures plus either CT of chest, abdomen, and pelvis, or whole-body PET/CT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate should be performed to confirm suspected stage I or II disease.</p><p></p><p>As with other sites of involvement, stage I or II EMZL of the salivary glands that can be encompassed within a single radiation field is often treated with RT, which may result in xerostomia. More advanced disease can be treated with single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or the combination of rituximab and chemotherapy. While a tissue biopsy is necessary to establish the diagnosis, more extensive surgery is discouraged since it can result in facial nerve injury, fistulas, and sialoceles.</p><p>In a retrospective study of 247 patients with salivary gland EMZL, initial therapy consisted of surgery and/or RT (57 percent); systemic chemotherapy and/or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (37 percent); and observation (6 percent) [<a href="#rid63">63</a>]. Median PFS was nine years and did not differ between those receiving localized versus systemic therapy. Other studies have reported median OS of up to 18 years in this population [<a href="#rid59">59,98</a>].</p><p>The use of systemic therapy in salivary gland EMZL is similar to that used for nodal marginal zone lymphoma. This is described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Choice of therapy'</a>.) </p><p class="headingAnchor" id="H1222791450"><span class="h3">Thyroid MZL</span><span class="headingEndMark"> — </span>Staging of patients with thyroid EMZL includes both an assessment of disease extent as well as studies for associated conditions. We perform the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination includes a detailed assessment of the eyes, ears, nose, and throat as well as the lymph node regions, liver, spleen, and skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies include complete blood count with differential, chemistries with liver and renal function, electrolytes, LDH, and serologic testing for HIV, hepatitis B virus, and hepatitis C virus. Given an association with Hashimoto's thyroiditis, we evaluate for hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging examination with CT of neck, chest, abdomen, and pelvis, or whole-body PET/CT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate should be performed to confirm suspected early (stage I/II) disease.</p><p></p><p>The data regarding treatment of these patients come from retrospective series and small prospective studies. For most patients with stage I or II thyroid EMZL that can be encompassed in a single radiation field, we suggest localized RT rather than other therapies. With this approach, responses are seen in over 90 percent with the majority attaining a CR [<a href="#rid99">99,100</a>]. Approximately 90 percent will be alive and free of recurrence at five years.</p><p>In addition to hypothyroidism from underlying Hashimoto thyroiditis or infiltration of the thyroid by the lymphoma, patients who receive radiation to the thyroid are at risk for developing primary hypothyroidism. The risk increases with higher doses of radiation and longer time interval from the initial radiation.</p><p>We recommend checking thyroid function within six months after high dose radiation and at least annually thereafter indefinitely (thyroid-stimulating hormone [TSH] for most patients). Additionally, children and young adults with radiation exposure to the thyroid should be monitored for radiation-associated thyroid neoplasia. This topic is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a> and  <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">"Disorders that cause hypothyroidism", section on 'External neck irradiation'</a> and  <a class="medical medical_review" href="/z/d/html/7059.html" rel="external">"Radiation-induced thyroid disease"</a>.)</p><p class="headingAnchor" id="H2187629585"><span class="h3">Lung MZL</span><span class="headingEndMark"> — </span>Primary lung EMZL is sometimes referred to as bronchial associated lymphoid tissue lymphoma. We perform the following staging studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination includes a detailed assessment of the eyes, ears, nose, and throat as well as the lymph node regions, liver, spleen, and skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies include complete blood count with differential, chemistries with liver and renal function, electrolytes, LDH, and serologic testing for HIV, hepatitis B virus, and hepatitis C virus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging examination includes either a CT of chest, abdomen, and pelvis, or a whole-body PET/CT with a dedicated chest CT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate should be performed to confirm suspected stage I or II disease.</p><p></p><p>A pathologic diagnosis is usually made based on a biopsy obtained using minimally invasive procedures such as transbronchial biopsy or image-guided percutaneous biopsy. Definitive resection, while associated with high CR rates, is usually unnecessary and has major short- and long-term risks [<a href="#rid101">101</a>].</p><p>We usually offer treatment with single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. Observation with serial imaging is an acceptable alternative for asymptomatic patients [<a href="#rid102">102</a>]. We avoid curative RT doses in this population because of the long-term morbidity associated with damage to normal lung tissue from RT. Low-dose RT of 4 Gy in two fractions can be offered to palliate patients with symptoms [<a href="#rid42">42,103</a>]. </p><p class="headingAnchor" id="H1914125893"><span class="h3">Small intestine MZL</span><span class="headingEndMark"> — </span>EMZL of the small intestine is also known as immunoproliferative small intestinal disease (IPSID), alpha heavy chain disease, Mediterranean lymphoma, and Seligman disease. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Lymphoma of the small intestine'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination should include an assessment of the lymph node regions, liver, spleen, and skin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of nutritional and performance status using the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper and lower endoscopy to evaluate the extent of gastrointestinal involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor biopsy should be tested for <em>H. pylori </em>and <em>Campylobacter jejuni</em>. If <em>H. pylori</em> is negative by histopathology, evaluate with noninvasive testing (stool antigen test or urea breath test). (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional laboratory studies include a complete blood count with differential, chemistries with liver and renal function, electrolytes, LDH, serum protein electrophoresis and immunofixation. Patients should undergo serologic testing for HIV, hepatitis B virus, and hepatitis C virus. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A contrast-enhanced CT scan of the chest, abdomen, and pelvis should be performed to evaluate for distant disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral bone marrow biopsy and aspirate should be performed to confirm suspected stage I or II disease.</p><p></p><p>IPSID is rare and few data are available for guiding treatment. Surgery is rarely indicated because intestinal involvement is generally diffuse. For patients who are diagnosed at an early stage, treatment with antibiotics directed against <em>C. jejuni</em> or <em>H. pylori</em> may lead to regression [<a href="#rid104">104-107</a>]. The choice of antibiotic is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2715.html" rel="external">"Campylobacter infection: Clinical manifestations, diagnosis, and treatment"</a>.)</p><p>Most patients ultimately relapse with an aggressive B cell lymphoma. For such patients, treatment is similar to the management of histologic transformation of follicular lymphoma to diffuse large B cell lymphoma. Five-year survival rates as high as 70 percent are seen in patients treated with combination chemotherapy plus <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> to control diarrhea and malabsorption [<a href="#rid108">108,109</a>]. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H1487049856"><span class="h3">Cutaneous MZL</span><span class="headingEndMark"> — </span>Primary cutaneous marginal zone lymphoma refers to those cases of EMZL that present in the skin when there is no evidence of extracutaneous disease after the completion of an initial staging evaluation. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4739.html" rel="external">"Primary cutaneous marginal zone lymphoma"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">HISTOLOGIC TRANSFORMATION</span><span class="headingEndMark"> — </span>An integral part of the natural history of all indolent non-Hodgkin lymphomas, including extranodal marginal zone lymphoma (EMZL), is progression to a higher grade histologic subtype, such as diffuse large B cell lymphoma [<a href="#rid110">110</a>].</p><p>Large cell transformation should be suspected in patients with systemic B symptoms (eg, fatigue, night sweats, weight loss), elevations in lactate dehydrogenase (LDH), and/or rapidly enlarging lymph nodes. If large cell transformation is suspected clinically, a positron emission tomography (PET) scan can help guide biopsy site selection.</p><p>There are few data to guide the selection of therapy in the setting of large cell transformation. We manage large cell transformation in a similar fashion to histologic transformation of follicular lymphoma. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4709.html" rel="external">"Autologous hematopoietic cell transplantation in follicular lymphoma", section on 'Following histologic transformation'</a>.)</p><p class="headingAnchor" id="H1225492097"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>As a whole, patients with EMZL have a relatively good prognosis with a median survival beyond 10 years [<a href="#rid111">111</a>]. However, EMZL is a heterogeneous disease and a prognostic score, called the "MALT-IPI" may be able to identify patients with high-risk disease that is more likely to progress.</p><p>The MALT-IPI was developed using prospective data from 401 patients receiving treatment for newly diagnosed EMZL and validated in a separate cohort of 633 patients [<a href="#rid112">112</a>]. Three independent adverse prognostic factors were identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥70 years</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III or IV  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum lactate dehydrogenase (LDH) level greater than the upper limit of normal</p><p></p><p>The following three risk groups and their corresponding five-year event-free survival (EFS), progression-free survival (PFS), overall survival (OS), and cause-specific survival (CSS) were:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (zero risk factors): EFS 70 percent, PFS 76 percent, OS 99 percent, CSS 100 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (one risk factor): EFS 56 percent, PFS 63 percent, OS 93 percent, CSS 98 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk (two or more risk factors): EFS 29 percent, PFS 33 percent, OS 64 percent, CSS 84 percent</p><p></p><p>A large, single-center analysis evaluated risk factors for histologic transformation to a higher grade lymphoma and its impact on survival [<a href="#rid110">110</a>]. In this cohort of 453 patients with biopsy-proven MZL, histologic transformation was documented at the time of diagnosis in seven patients and subsequently in 27 patients. Histologic transformation was more likely in those with an elevated LDH, &gt;4 nodal sites involved, and failure to achieve a complete remission after initial treatment. Patients with histologic transformation had lower five-year survival rates (65 versus 86 percent).</p><p class="headingAnchor" id="H1437483722"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122004.html" rel="external">"Society guideline links: Marginal zone lymphoma"</a>.)</p><p class="headingAnchor" id="H12764592"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Extranodal marginal zone lymphoma (EMZL) of mucosa associated lymphoid tissue (also called MALT lymphoma) is a clinically indolent B cell non-Hodgkin lymphoma that arises in epithelial tissues. While it has a tendency to remain localized to the tissue of origin for long periods of time, it frequently recurs locally and has potential for systematic spread and transformation to an aggressive B cell lymphoma.</p><p></p><p class="bulletIndent1">For treatment purposes, EMZL is separated into those developing in the stomach (gastric EMZL) and those developing in non-gastric extranodal locations. Of importance, patients with EMZL of any site and stage who demonstrate coexistent large cell lymphoma are treated as diffuse large B cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric EMZL</strong> – The treatment of gastric EMZL is dictated primarily by the disease stage  (<a class="graphic graphic_table graphicRef65686" href="/z/d/graphic/65686.html" rel="external">table 3</a>) and the presence or absence of a concomitant <em>H. pylori</em> infection  (<a class="graphic graphic_algorithm graphicRef115197" href="/z/d/graphic/115197.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with <em>H. pylori</em> infection should receive <em>H. pylori</em> eradication therapy. For patients who have stage I or II <em>H. pylori</em>-positive gastric EMZL, we recommend initial <em>H. pylori</em> eradication therapy followed by surveillance rather than immediate radiation therapy (RT) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). A choice among <em>H. pylori</em> eradication regimens depends on availability and patient-related factors. (See <a class="local">'H. pylori eradication'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have stage I or II <em>H. pylori</em>-negative gastric EMZL that can be encompassed in a single radiation field, we suggest initial treatment with local RT rather than <em>H. pylori</em> eradication therapy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and/or chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with stage IV gastric EMZL we suggest treatment with <em>H. pylori</em> eradication therapy if <em>H. pylori</em>-positive followed by observation until the development of symptoms at which time chemotherapy is initiated rather than immediate treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and/or chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Advanced stage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients are evaluated after the completion of treatment to determine whether the <em>H. pylori</em> was successfully eradicated (if appropriate) and whether there has been a tumor response. (See <a class="local">'Response evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-gastric EMZL</strong> – The treatment of non-gastric EMZL depends principally on the stage of disease and area involved:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with stage I or II non-gastric EMZL that can be encompassed in a single radiation field, we suggest treatment with involved-site RT rather than other treatment modalities (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatively, a subset of patients with stage I disease may be observed initially with plans to initiate RT at the time of disease progression. (See <a class="local">'Stage I or II disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with more advanced stage non-gastric EMZL, we suggest treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> with or without chemotherapy in a similar fashion to that used for nodal marginal zone lymphoma (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/z/d/html/113327.html" rel="external">"Nodal marginal zone lymphoma", section on 'Choice of therapy'</a> and <a class="local">'Stage III or IV disease'</a> above.)</p><p></p><p class="bulletIndent1">Some sites of involvement require adjustments to the pretreatment evaluation and management strategy given the risks of radiation toxicity and underlying comorbidity. Importantly, we avoid curative RT doses to sites of lung involvement because of the long-term morbidity associated with damage to normal lung tissue from RT. (See <a class="local">'Site-specific considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic transformation</strong> – Large cell transformation should be suspected in patients with systemic B symptoms (eg, fatigue, night sweats, weight loss), elevations in lactate dehydrogenase, and/or rapidly enlarging lymph nodes. If large cell transformation is suspected clinically, a positron emission tomography (PET) scan can help guide biopsy site selection. (See <a class="local">'Histologic transformation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed on March 11, 2020).</li><li><a class="nounderline abstract_t">Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:17.</a></li><li><a class="nounderline abstract_t">Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007; 79:205.</a></li><li><a class="nounderline abstract_t">Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16:473.</a></li><li><a class="nounderline abstract_t">Hoffmann M, Kletter K, Becherer A, et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64:336.</a></li><li><a class="nounderline abstract_t">Alderuccio JP, Reis IM, Koff JL, et al. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 2023; 141:1888.</a></li><li><a class="nounderline abstract_t">Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397.</a></li><li><a class="nounderline abstract_t">Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3874.</a></li><li><a class="nounderline abstract_t">Liu HT, Hsu C, Chen CL, et al. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. Am J Hematol 2000; 64:175.</a></li><li><a class="nounderline abstract_t">Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 2004; 240:28.</a></li><li><a class="nounderline abstract_t">Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004; 45:1847.</a></li><li><a class="nounderline abstract_t">Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575.</a></li><li><a class="nounderline abstract_t">Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995; 122:767.</a></li><li><a class="nounderline abstract_t">Bayerdörffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345:1591.</a></li><li><a class="nounderline abstract_t">Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131:88.</a></li><li><a class="nounderline abstract_t">Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97:1345.</a></li><li><a class="nounderline abstract_t">Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002; 99:2541.</a></li><li><a class="nounderline abstract_t">Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23:8018.</a></li><li><a class="nounderline abstract_t">Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009; 20:1086.</a></li><li><a class="nounderline abstract_t">Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61:507.</a></li><li><a class="nounderline abstract_t">Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52:1058.</a></li><li><a class="nounderline abstract_t">Tomita N, Kodaira T, Tachibana H, et al. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol 2009; 90:231.</a></li><li><a class="nounderline abstract_t">Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21:4157.</a></li><li><a class="nounderline abstract_t">Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 2013; 24:1344.</a></li><li><a class="nounderline abstract_t">Ruskoné-Fourmestraux A, Matysiak-Budnik T, Fabiani B, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up. Radiother Oncol 2015; 117:178.</a></li><li><a class="nounderline abstract_t">Alpen B, Neubauer A, Dierlamm J, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000; 95:4014.</a></li><li><a class="nounderline abstract_t">Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101:2547.</a></li><li><a class="nounderline abstract_t">Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98:1182.</a></li><li><a class="nounderline abstract_t">Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106:1037.</a></li><li><a class="nounderline abstract_t">Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009; 144:367.</a></li><li><a class="nounderline abstract_t">Zullo A, Hassan C, Cristofari F, et al. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010; 2:181.</a></li><li><a class="nounderline abstract_t">Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi144.</a></li><li><a class="nounderline abstract_t">Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013; 160:47.</a></li><li><a class="nounderline abstract_t">Shiozawa E, Norose T, Kaneko K, et al. Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol 2009; 24:307.</a></li><li><a class="nounderline abstract_t">Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003; 52:1656.</a></li><li><a class="nounderline abstract_t">Alpen B, Kuse R, Parwaresch R, et al. Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. J Clin Oncol 2004; 22:3039.</a></li><li><a class="nounderline abstract_t">Noy A, Yahalom J, Zaretsky L, et al. Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol 2005; 23:3768.</a></li><li><a class="nounderline abstract_t">Schreuder MI, Hoeve MA, Groothuis L, et al. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br J Haematol 2005; 131:619.</a></li><li><a class="nounderline abstract_t">Fischbach W, Goebeler-Kolve M, Starostik P, et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360:547.</a></li><li><a class="nounderline abstract_t">Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89:1350.</a></li><li><a class="nounderline abstract_t">Pinnix CC, Gunther JR, Milgrom SA, et al. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 2019; 104:447.</a></li><li><a class="nounderline abstract_t">Wirth A, Mikhaeel NG, Aleman BMP, et al. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys 2020; 107:909.</a></li><li><a class="nounderline abstract_t">De Leo AN, Bates JE, Lockney NA, et al. Radiotherapy in Early-stage Gastric MALT: Improved Survival Without Increased Cardiac Death. Am J Clin Oncol 2020; 43:770.</a></li><li><a class="nounderline abstract_t">Fang P, Gunther JR, Pinnix CC, et al. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys 2021; 109:1414.</a></li><li><a class="nounderline abstract_t">Yahalom J, Xu AJ, Noy A, et al. Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. Blood Adv 2021; 5:1830.</a></li><li><a class="nounderline abstract_t">Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23:1979.</a></li><li><a class="nounderline abstract_t">Datta YH, Kampalath B, Binion DG. Rituximab-induced remission of a gastric MALT lymphoma. Leuk Lymphoma 2004; 45:1297.</a></li><li><a class="nounderline abstract_t">Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102:2741.</a></li><li><a class="nounderline abstract_t">Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol 2013; 24:1352.</a></li><li><a class="nounderline abstract_t">Raderer M, Streubel B, Wöhrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55:616.</a></li><li><a class="nounderline abstract_t">Strati P, Lee ST, Teegavarupu P, et al. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 2019; 94:E150.</a></li><li><a class="nounderline abstract_t">Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92:11.</a></li><li><a class="nounderline abstract_t">Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys 2014; 88:650.</a></li><li><a class="nounderline abstract_t">Isobe K, Kagami Y, Higuchi K, et al. A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys 2007; 69:1181.</a></li><li><a class="nounderline abstract_t">Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50:1258.</a></li><li><a class="nounderline abstract_t">Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys 2010; 77:86.</a></li><li><a class="nounderline abstract_t">Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010; 116:3815.</a></li><li><a class="nounderline abstract_t">Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011; 81:e659.</a></li><li><a class="nounderline abstract_t">Anacak Y, Miller RC, Constantinou N, et al. Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2012; 82:315.</a></li><li><a class="nounderline abstract_t">Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:1509.</a></li><li><a class="nounderline abstract_t">Olszewski AJ, Desai A. Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Radiat Oncol Biol Phys 2014; 88:642.</a></li><li><a class="nounderline abstract_t">Woolf DK, Kuhan H, Shoffren O, et al. Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy. Clin Oncol (R Coll Radiol) 2015; 27:153.</a></li><li><a class="nounderline abstract_t">Jackson AE, Mian M, Kalpadakis C, et al. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist 2015; 20:1149.</a></li><li><a class="nounderline abstract_t">Desai A, Joag MG, Lekakis L, et al. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood 2017; 129:324.</a></li><li><a class="nounderline abstract_t">Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol 2017; 28:1064.</a></li><li><a class="nounderline abstract_t">MacManus MP, Roos D, O'Brien P, et al. Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. Eur J Cancer 2021; 152:129.</a></li><li><a class="nounderline abstract_t">Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol 2014; 15:457.</a></li><li><a class="nounderline abstract_t">Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol 2021; 22:332.</a></li><li><a class="nounderline abstract_t">Imber BS, Chau KW, Lee J, et al. Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? Blood Adv 2021; 5:4185.</a></li><li><a class="nounderline abstract_t">Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57:1382.</a></li><li><a class="nounderline abstract_t">Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 2003; 98:865.</a></li><li><a class="nounderline abstract_t">Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 2003; 57:172.</a></li><li><a class="nounderline abstract_t">Suh CO, Shim SJ, Lee SW, et al. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 2006; 65:228.</a></li><li><a class="nounderline abstract_t">Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 2006; 108:1451.</a></li><li><a class="nounderline abstract_t">Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802.</a></li><li><a class="nounderline abstract_t">Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004; 100:2190.</a></li><li><a class="nounderline abstract_t">Avilés A, Neri N, Calva A, et al. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit. Oncology 2006; 70:173.</a></li><li><a class="nounderline abstract_t">Merli M, Rattotti S, Spina M, et al. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. J Clin Oncol 2022; 40:4060.</a></li><li><a class="nounderline abstract_t">Grünberger B, Wöhrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24:1370.</a></li><li><a class="nounderline abstract_t">Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005; 11:3349.</a></li><li><a class="nounderline abstract_t">Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24:3136.</a></li><li><a class="nounderline abstract_t">Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83:454.</a></li><li><a class="nounderline abstract_t">Chae H, Cho H, Sa HS, et al. The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis. Br J Haematol 2021; 193:848.</a></li><li><a class="nounderline abstract_t">Coupland SE, White VA, Rootman J, et al. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 2009; 133:1262.</a></li><li><a class="nounderline abstract_t">Kaushik M, Pulido JS, Schild SE, Stafford S. Risk of radiation retinopathy in patients with orbital and ocular lymphoma. Int J Radiat Oncol Biol Phys 2012; 84:1145.</a></li><li><a class="nounderline abstract_t">Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59:139.</a></li><li><a class="nounderline abstract_t">Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 2016; 66:153.</a></li><li><a class="nounderline abstract_t">Saul EE, Alderuccio JP, Reis IM, et al. Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma. Am J Hematol 2023; 98:148.</a></li><li><a class="nounderline abstract_t">Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006; 17:135.</a></li><li><a class="nounderline abstract_t">Husain A, Roberts D, Pro B, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 2007; 110:809.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; 23:5067.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006; 98:1375.</a></li><li><a class="nounderline abstract_t">Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010; 150:226.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30:2988.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96:586.</a></li><li><a class="nounderline abstract_t">Han JJ, Kim TM, Jeon YK, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol 2015; 94:575.</a></li><li><a class="nounderline abstract_t">Ferreri AJM, Sassone M, Miserocchi E, et al. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. Blood Adv 2020; 4:1013.</a></li><li><a class="nounderline abstract_t">Vazquez A, Khan MN, Sanghvi S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck 2015; 37:18.</a></li><li><a class="nounderline abstract_t">Watanabe N, Noh JY, Narimatsu H, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease. Br J Haematol 2011; 153:236.</a></li><li><a class="nounderline abstract_t">Oh SY, Kim WS, Kim JS, et al. Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study. Acta Haematol 2012; 127:100.</a></li><li><a class="nounderline abstract_t">Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2010; 89:563.</a></li><li><a class="nounderline abstract_t">Joffe E, Leyfman Y, Drill E, et al. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Adv 2021; 5:345.</a></li><li><a class="nounderline abstract_t">Girinsky T, Paumier A, Ferme C, et al. Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys 2012; 83:e385.</a></li><li><a class="nounderline abstract_t">Nagashima R, Takeda H, Maeda K, et al. Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Gastroenterology 1996; 111:1674.</a></li><li><a class="nounderline abstract_t">Matsumoto T, Iida M, Shimizu M. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. Lancet 1997; 350:115.</a></li><li><a class="nounderline abstract_t">Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989; 63:1251.</a></li><li><a class="nounderline abstract_t">Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350:239.</a></li><li><a class="nounderline abstract_t">el Saghir NS, Jessen K, Mass RE, et al. Combination chemotherapy for primary small intestinal lymphoma in the Middle East. Eur J Cancer Clin Oncol 1989; 25:851.</a></li><li><a class="nounderline abstract_t">Akbulut H, Soykan I, Yakaryilmaz F, et al. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer 1997; 80:8.</a></li><li><a class="nounderline abstract_t">Alderuccio JP, Zhao W, Desai A, et al. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. J Clin Oncol 2018; :JCO1800138.</a></li><li><a class="nounderline abstract_t">Qi S, Liu X, Noy A, et al. Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study. Blood Adv 2023; 7:1496.</a></li><li><a class="nounderline abstract_t">Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood 2017; 130:1409.</a></li></ol></div><div id="topicVersionRevision">Topic 4710 Version 69.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed on March 11, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912792" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662066" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668266" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759529" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735908" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8075046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559725" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861812" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213615" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The diminishing role of surgery in the treatment of gastric lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223645" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Conservative management of gastric lymphoma: the treatment option of choice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102719" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717599" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7783535" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419446" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174856" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895791" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204012" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19193705" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890816" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11958902" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135751" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14615444" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293112" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26395311" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10939796" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517817" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493468" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845895" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036078" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160595" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24078657" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23043300" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032451" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14570741" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284253" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15923573" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16351637" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241663" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308704" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30769175" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272184" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32841963" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Radiotherapy in Early-stage Gastric MALT: Improved Survival Without Increased Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33309978" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33787863" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668468" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15360017" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rituximab-induced remission of a gastric MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842999" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348804" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16299027" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785215" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25863750" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24521680" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601683" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483337" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Stage I and II MALT lymphoma: results of treatment with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632068" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564130" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21640514" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21075560" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664061" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411627" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455843" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26268740" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789481" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327924" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34098462" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572077" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539729" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529789" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630277" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910532" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909230" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503386" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638927" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648389" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139063" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763405" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714311" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549831" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867234" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769982" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945490" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779995" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19653722" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A TNM-based clinical staging system of ocular adnexal lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592046" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk of radiation retinopathy in patients with orbital and ocular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325441" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Orbital lymphoma: radiotherapy outcome and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26773441" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35560252" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236754" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17594698" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15968003" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018784" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20433679" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22802315" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100336" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338969" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182364" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733777" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371004" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178776" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20024551" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33496731" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22420970" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8942749" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228971" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920354" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724303" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Immunoproliferative small intestinal disease associated with Campylobacter jejuni.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2472276" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Combination chemotherapy for primary small intestinal lymphoma in the Middle East.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9210703" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30312133" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399527" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28720586" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A MALT lymphoma prognostic index.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
